louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00602615: Bioequivalency Study of Torsemide Tablets Under Fed Conditions
Official title: A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalency Study of 20 mg Torsemide Tablets Under Fed Conditions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Edema
Lead sponsor: West-Ward Pharmaceutical
Sponsor class: INDUSTRY
First posted: 2008-01-28
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The objective of this study was the bioequivalence of a Roxane Laboratories' Torsemide Tablets, 20 mg, to Demadex® Tablets, 20 mg (Roche) under fed conditions using a single-dose, 2-treatment, 2-period, crossover design.


Eligibility criteria: Inclusion Criteria:

* No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening.

Exclusion Criteria:

* Positive test for HIV, Hepatitis B, or Hepatitis C.
* Treatment with known enzyme altering drugs.
* History of allergic or adverse response to Torsemide or any comparable or similar product.

Primary outcomes:
measure: Bioequivalence
timeFrame: Baseline, Two period, Seven day washout
Secondary outcomes:
Other outcomes:
Locations:
city: Springfield
country: United States
facility: Bio-Kinetic Clinical Applications, Inc.
state: Missouri
Study officials:
affiliation: Bio-Kinetic Clinical Applications, Inc.
name: Dennis Morrison, DO
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06954415: The Clinical Application of EIT in Clinically Ill Patients: a Cross-sectional Study
Official title: The Clinical Application of Electrical Impedance Tomography in Clinically Ill Patients: a Cross-sectional Study
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Electrical Impedance Tomography (EIT)
Lead sponsor: Shanghai Zhongshan Hospital
Sponsor class: OTHER
First posted: 2025-05-01
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Doctors/respiratory therapists with experience in EIT application in Chinese intensive care units

Brief summary: The application of electrical impedance tomography (EIT) in intensive care is increasing. It can provide additional information on individual respiratory physiology of patients, enabling clinicians or respiratory therapists to monitor patients' respiratory responses to different ventilator settings, respiratory treatment methods or clinical evolution, and thus achieve more personalized mechanical ventilation methods. Although this technology provides a large amount of valuable information, there is still uncertainty about how to use it and interpret the results in critically ill patients. Therefore, the evidence that EIT-guided ventilation strategies can improve prognosis is still in its infancy. Through this survey, the investigators aim to understand the current experiences and guiding roles of EIT in clinical practice. The secondary objective is to learn about the current challenges of EIT in clinical and practical settings, as well as the factors that promote or hinder the implementation of EIT monitoring technology.


Eligibility criteria: Inclusion Criteria:

* occupation is "respiratory therapist or part-time respiratory therapy doctor/nurse";
* work city or area belongs to China;
* to complete electronic questionnaires to fill out and submit.

Exclusion Criteria:

* work city or area not belongs to China;
* The questionnaire is not completed or quit midway;
* Other invalid questionnaires.

Primary outcomes:
measure: Frequency of EIT usage
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02470715: Identifying Molecular Drivers of Cancer
Official title: Identifying Molecular Drivers of Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cancer
Tumor
Advanced Cancer
Keywords: genetic sequencing
genome
cancer
DNA
RNA
protein
metabolite
Lead sponsor: Avera McKennan Hospital & University Health Center
Sponsor class: OTHER
First posted: 2015-06-12
Enrollment: 579
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who have been diagnosed with cancer

Brief summary: The primary aim of this study is to identify drivers of cancer by performing comprehensive genetic, proteomic, and metabolomic characterization of patient samples as a basis for understanding the underlying cause of disease.

Detailed description: This study involves looking at the DNA, RNA, proteins, and metabolites in blood and tissue samples collected from subjects and linking them to their health information. By doing so, researchers hope to discover the underlying molecular causes of human diseases with the hope that this information can be used for the development of diagnostic tests and more effective treatments.

Eligibility criteria: Inclusion Criteria:

* Patients diagnoses with cancer but healthy enough to undergo a biopsy procedure
* Between the ages of 18 and 100

Exclusion Criteria:

* Patients who are pregnant

Primary outcomes:
measure: Genetic profiling
timeFrame: Up to 15 years
Secondary outcomes:
Other outcomes:
Locations:
city: Sioux Falls
country: United States
facility: Avera Cancer Institute
state: South Dakota
Study officials:
affiliation: Avera McKennan Hospital & University Health Center
name: Brian Leyland-Jones
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05549115: Susceptibility-Guided Sequential Therapy for Helicobacter Pylori Infection
Official title: Susceptibility-Guided Sequential Therapy Versus Empirical Therapy for Helicobacter Pylori Infection: a Randomised Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Helicobacter Pylori Infection
Keywords: Helicobacter pylori
Drug Resistance, Microbial
Microbial Sensitivity Tests
Lead sponsor: Liaocheng People's Hospital
Sponsor class: OTHER
First posted: 2022-09-22
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main objective of this trial is to assess whether a sequential therapy strategy based on molecular antibiotic susceptibility testing (including clarithromycin and fluoroquinolone) for H. pylori infection will improve the eradication rate compared to an empirical therapy.

Detailed description: This trial is designed as a prospective, randomised, open-label, active-controlled and single-centre study. For empirical therapy group(control group), Bismuth quadruple therapy will be an empirical first-line therapy, and high dose dual (proton-pump inhibitor + amoxicillin) treatment will be for rescue therapy if the first-line empirical treat failure. For the susceptibility-guided sequential therapy group, regimens were selected based on H. pylori susceptibility to clarithromycin and levofloxacin. The primary outcome is the first-line eradication rate in both groups, and the overall (including first- and rescue therapies) H. pylori eradication rates in both groups is one of the secondary outcomes. The eradication rates of H. pylori will be analysed by intention-to-treat analysis, modified intention-to-treat analysis and per-protocol analysis.

Eligibility criteria: Inclusion Criteria:

* H. pylori infection was determined using at least one of the following tests: 13C/14C-urea breath test (UBT), stool H. pylori antigen test, rapid urease test, and histological analysis within 4 weeks.
* Patients were naïve to H. pylori treatment.

Exclusion Criteria:

* Allergy to any drug administered.
* Pregnancy and lactation.
* Major systemic diseases, such as severe cardiopulmonary or liver dysfunction.
* Complicated with active peptic ulcer disease, gastric cancer, or prior gastrectomy.

Primary outcomes:
measure: the first-line H. pylori eradication rate
timeFrame: 4-8 weeks after the end of treatment.
Secondary outcomes:
measure: the rescue H. pylori eradication rate
timeFrame: 4-8 weeks after the second treatment
measure: the overall H.pylori eradication rate
timeFrame: 4-8 weeks after the second treatment
measure: high-dose dual therapy eradication rate
timeFrame: 4-8 weeks after the second treatment
measure: Adverse events and compliance
timeFrame: 3 days after the end of treatment.
Other outcomes:
Locations:
city: Liaocheng
country: China
facility: Liaocheng people's hospital
state: Shandong
Study officials:
affiliation: Liaocheng People's Hospital
name: Jing run Zhao, Dr
role: STUDY_CHAIR
References:
Clinical trial NCT05246215: Diagnostic Values of Galectin-3, Soluble ST2 and BNP in Predicting the Clinical Outcome of ST-Segment Elevation Myocardial Infarction Patients
Official title: Diagnostic Values of Galectin-3, Soluble ST2 and BNP in Predicting the Clinical Outcome of ST-Segment Elevation Myocardial Infarction Patients
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: ST Elevation Myocardial Infarction
HF - Heart Failure
Stable Angina
Keywords: Galectin-3
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2022-02-18
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Assuit University Hospital.

Brief summary: An acute ST-elevation myocardial infarction occurs due to occlusion of one or more coronary arteries, causing transmural myocardial ischemia which in turn results in myocardial injury or necrosis. Acute myocardial infarction (AMI) may lead to the development of heart failure (HF). Accessible diagnostic tools commonly used in HF such as natriuretic peptides and (NYHA) classiﬁcation reﬂect already overt clinical HF. Troponin and creatine kinase reﬂect myocardial damage, but their usefulness in predicting long-term LVR is limited. Recent guidelines on HF management stressed that HF onset may be delayed or prevented through certain Interventions, such as pharmacotherapy ,post infarction rehabilitation, or modiﬁcation of HF risk factors. Therefore, it is important to identify potential markers, which would be more informative of HF preclinical stages to recognize patients with an increased risk of HF onset, and to start treatment in advance (1) Gal-3 participates in inﬂammation and pro ﬁbrotic pathways, while sST2 is a biomarker of inﬂammation, cardiac mechanical strain, and tissue ﬁbrosis, both of which may predict LVR (2).

sST is a biomarker of inﬂammation, cardiac mechanical strain, and tissue ﬁbrosis(3).

B_type natriuretic peptide (BNP) is elevated in acute myocardial infarction and is a quantitative biochemical marker related to the extent of infarction and left ventricular systolic dysfunction(4).


Eligibility criteria: Inclusion Criteria:

1. Age ≥ 18 years.
2. Hospital admission due to ﬁrst-time STEMI treated with pPCI.

Exclusion Criteria:

* History of previous acute coronary syndrome, Previously diagnosed HF or asymptomatic LV dysfunction with LVEF \<50% or previously diagnosed signiﬁcant valvular disease or any other previously diagnosed structural heart disease Severe renal dysfunction, Severe liver disease, Chronic inﬂammatory disease, Current neoplastic disease

Primary outcomes:
measure: investigate the association of Gal-3, sST2 and BNP concentrations and the development of clinically overt HF in patients after ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention
timeFrame: 7 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03805815: Clinical Implication of the Tunable Crack Sensor
Official title: Development of Diagnosis Algorism for Paroxysmal Arrhythmia Using Ultra-thin Resistive Membrane: a Pilot Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Blood Pressure
Keywords: blood pressure
crack sensor
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2019-01-16
Enrollment: 30
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A case of suspected coronary artery disease for the purpose of coronary angiography

Brief summary: \[Development of diagnosis algorism for paroxysmal arrhythmia using ultra-thin resistive membrane: a pilot study\] Comparison of blood pressure via tunable crack sensor and invasive pressure wire

Detailed description: To develop a diagnosis algorism for paroxysmal arrhythmia using ultra-thin resistive membrane, we will compare the blood pressure measured via a tunable crack sensor and that measured by a invasive pressure wire

Eligibility criteria: Inclusion Criteria:

A case of suspected coronary artery disease at Seoul National University Hospital for the purpose of coronary angiography

* At least 19 years old
* If he/she hears enough explanation about clinical research and intends to participate in clinical research himself

Exclusion Criteria:

* Under 19 years old
* Refusal to participate in clinical studies
* If the cognitive function is weak enough not to understand the explanation of the clinical study and to make voluntary decisions accordingly

Primary outcomes:
measure: Blood pressure monitoring using tunable crack sensor
timeFrame: immediately
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul national university hospital
Study officials:
affiliation: Seoul National University Hospital
name: Bon-Kwon Koo
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kang D, Pikhitsa PV, Choi YW, Lee C, Shin SS, Piao L, Park B, Suh KY, Kim TI, Choi M. Ultrasensitive mechanical crack-based sensor inspired by the spider sensory system. Nature. 2014 Dec 11;516(7530):222-6. doi: 10.1038/nature14002.
Clinical trial NCT05322915: Therapeutic Effects of Line Dancing in People With MS
Official title: Therapeutic Effects of Line Dancing in People With Multiple Sclerosis: an Evaluator-blinded, Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Multiple Sclerosis
Keywords: line dance
balance
anxiety
depression
quality of life
Multiple Sclerosis
Lead sponsor: Gazi University
Sponsor class: OTHER
Collaborators: name: Hacettepe University
name: Fenerbahce University
First posted: 2022-04-12
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of this study is to analyze the effects of line dancing on balance, anxiety, depression and quality of life for people with multiple sclerosis (PwMS).

Detailed description: Purpose: The objective of this study is to analyze the effects of line dancing on balance, anxiety, depression and quality of life for people with multiple sclerosis (PwMS).

Methods: This study was conducted prospective parallel-group design study. 31 PwMS were randomized two groups. The dance group undertook 60-minute sessions twice a week for four weeks and the control group did not do any particular training during this period. The outcome were measured using the Berg Balance Scale (BBS), Hospital Anxiety and Depression Scale (HADS), and Multiple Sclerosis Quality of Life-54 (MSQoL-54) by an evaluator blinded to the study.

Eligibility criteria: Inclusion Criteria:

* Between 18-65 years,
* EDSS \[22\]\<6,
* Mini-Mental State Examination score \>24.

Exclusion Criteria:

* exacerbations within the previous three months,
* have other physical, neurological problems,
* changeable health status.
* havig a cardiovascular disorder

Primary outcomes:
measure: Berg Balance Scale
timeFrame: 4 weeks
Secondary outcomes:
measure: Hospital Anxiety and Depression Scale
timeFrame: 4 weeks
measure: Multiple Sclerosis Quality of Life-54
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Hacettepe University
Study officials:
affiliation: Hacettepe University
name: Gamze Ekici Çağlar, Prof
role: STUDY_DIRECTOR
References:
Clinical trial NCT04760015: Characteristics of Patients With Dementia Who Are Screaming in Nursing Homes
Official title: Characteristics of Patients With Disruptive Vocalizations Residing in Nursing Homes Supported by the Mobile Gerontopsychiatry Team : Retrospective Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Dementia
Keywords: Dementia disease
Disruptives vocalizations
agitation
cries
profil
characteristics
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2021-02-18
Enrollment: 60
Sex: ALL
Minimum age (years): 75
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Residents in nursing homes, aged 75 years old and more. They have dementia with agitation, including diruptives vocalizations.

Brief summary: Patients with dementia develop behavioral problems over time. Among these, the investigators object screams or cries or disruptives vocalizations. Their cause is multifactorial and their management difficult in nursing homes. Often this patients are polymedicated, sedated or/and isolated.

Many scientific studies are interested in drug and non-drug treatments. In this study, the investigators are looking for a profile for disruptives vocalizations's patients. Thus, the investigators will study the global profile of demented patients residing in EHPAD to determine if there are any similarities between them.


Eligibility criteria: Inclusion criteria:

* aged 75 years old and more
* living in nursing homes
* dementia
* agitation and disruptives vocalizations
* twice and more interventions by the Mobile Gerontopsychiatry Team

Exclusion criteria:

- no follow-up after team intervention

Primary outcomes:
measure: Describe the profile of demented patients
timeFrame: 2 years
Secondary outcomes:
measure: Efficiency of MGT's intervention on screams
timeFrame: 2 years
measure: Determination of predictive factors for MGT's effectiveness.
timeFrame: 2 years
measure: Determination if the delay between the symptom's beginning and intervention can influence their effectiveness.
timeFrame: 2 years
measure: Determination if disruptives vocalizations could be a dementia premorbid symptom.
timeFrame: 2 years
Other outcomes:
Locations:
city: Montpellier
country: France
facility: Uhmontpellier
Study officials:
affiliation: University Hospital, Montpellier
name: Marie-Suzanne Leglise, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06847815: Corn Glycemic Index
Official title: Determination of the Glycemic Index of Differently Processed Sweet Corn
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Glycemic Index
Keywords: sweet corn
glycemic index
Lead sponsor: University of Florida
Sponsor class: OTHER
First posted: 2025-02-26
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: Processing sweet corn may impact digestibility and, therefore, glycemic response following consumption. The primary aim of this study is to assess the glycemic index of various sweet corn products and varieties. An exploratory aim is to assess hunger/satiety scores following sweet corn intake.


Eligibility criteria: Inclusion Criteria:

* Able to provide written consent in English
* Willing to consume 50 g of glucose in less than 15 minutes (2 mornings)
* Willing to consume around 250 to 350 g of sweet corn in 10 to 15 minutes (3 mornings)
* Willing to provide 7 capillary blood samples by fingerstick (by fine lancet) during each 2-hour session

Exclusion Criteria:

* Metabolic disease or condition affecting blood glucose, such as diabetes type 1 and 2, metabolic syndrome, or polycystic ovary syndrome
* Baseline fasting blood glucose \> 100 mg/dL
* Currently pregnant

Primary outcomes:
measure: iAUC
timeFrame: From enrollment to the end of 5 weeks.
Secondary outcomes:
measure: Hunger and Satiety Score
timeFrame: From enrollment to the end of 5 weeks.
Other outcomes:
Locations:
city: Gainesville
country: United States
facility: Food Science and Human Nutrition Building
state: Florida
city: Gainesville
country: United States
facility: University of Florida
state: Florida
Study officials:
References:
Clinical trial NCT05412615: PRC With Meniscal Allograft Arthroplasty for Wrist Osteoarthritis
Official title: Proximal Row Carpectomy With Meniscal Allograft Arthroplasty for Wrist Osteoarthritis
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Wrist Osteoarthritis
Lead sponsor: University of Colorado, Denver
Sponsor class: OTHER
First posted: 2022-06-09
Enrollment: 20
Sex: ALL
Minimum age (years): 30
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study plans to learn more about the effect of adding tissue graft for wrist osteoarthritis reconstruction procedures. Previous studies have shown better allograft stability, and no documented foreign body reaction than with silicone and other synthetic materials.


Eligibility criteria: Inclusion Criteria:

* symptomatic wrist arthritis associated with SLAC or SNAC pathology
* Patients 30 years or older or 80 years or younger

Exclusion Criteria:

* Patients younger than 29 years or older than 80 years
* History of previous surgery related to wrist osteoarthritis

Primary outcomes:
measure: DISABILITIES OF THE ARM, SHOULDER AND HAND Score: Baseline/Pre-op
timeFrame: Preoperatively
measure: DISABILITIES OF THE ARM, SHOULDER AND HAND Score: 2 weeks
timeFrame: 2 weeks
measure: DISABILITIES OF THE ARM, SHOULDER AND HAND Score: 6 weeks
timeFrame: 6 weeks
measure: DISABILITIES OF THE ARM, SHOULDER AND HAND Score: 3 months
timeFrame: 3 months
measure: DISABILITIES OF THE ARM, SHOULDER AND HAND Score: 6 months
timeFrame: 6 months
measure: DISABILITIES OF THE ARM, SHOULDER AND HAND Score: 9 months
timeFrame: 9 months
measure: DISABILITIES OF THE ARM, SHOULDER AND HAND Score: 12 months
timeFrame: 12 months
measure: DISABILITIES OF THE ARM, SHOULDER AND HAND Score: 24 months
timeFrame: 24 months
Secondary outcomes:
measure: Pain Score
timeFrame: Preoperatively, up to 24 Months
measure: Radiographic joint spacing
timeFrame: 3 months, up to 24 Months
measure: MRI Joint Spacing
timeFrame: 9 Months, 24 Months
Other outcomes:
Locations:
city: Englewood
country: United States
facility: UCHealth Steadman Hawkins Clinic Inverness
state: Colorado
Study officials:
References: